In a preclinical study by Furomoto et al., the 18F-labelled MMP-2 inhibitors’ (18F-SAV03M) role was evaluated, with results that suggest these radiopharmaceuticals as potential and suitable tracers for tumor imaging with PET [68]. Here, MMP2 is linked to neoplasm.